Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
By Charles E. Geyer, J. Forster, Deborah L. Lindquist, Stephen Chan, C. Romieu, T. Pieńkowski, A. Jagiełło-Gruszfeld, J. Crown, A. Chan, Bella Kaufman and 8 more. New England Journal of Medicine, 2006
3,372 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/ce25c54bd3a91a67f101b79b4f55dce77725e67b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “71) NS 3 [97]”
- Targeting the cancer kinome through polypharmacology (2010, neutral): “Unlike CML, however, the clinical response to lapatinib in metastatic breast cancer is brief, and disease progression typically occurs within a few months 14 .”
- Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (2008, background): “Trastuzumab (5, 35–41) and, more recently, lapatinib (42) are approved for clinical use in women whose breast cancer overexpresses HER2.”
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 (2016, background): “Several HER2-targeting therapies such as trastuzumab (6, 7), lapatinib (8), pertuzumab (9), and T-DM1 (10) have been approved worldwide for patients with HER2-positive tumors, which are defined as either IHC 3þ or IHC 2þ/FISH– positive.”